Condition: Triple Negative Breast Neoplasms · Sponsor: UNICANCER
The goal of this clinical trial is to evaluate the efficacity and safety of pembrolizumab and capecitabine on the invasive disease-free survival, in participants who have triple negative breast cancer (TNBC) with residual disease after neoadjuvant chemotherapy associated with pembrolizumab.
This description comes directly from the study's public registry record.
Telma ROQUE, PhD · +33 (0) 1 80 50 12 92 · cappa@unicancer.fr
Sylvie Mijonnet, PhD · +33 (0) 1 44 23 04 65 · s-mijonnet@unicancer.fr
Always discuss trial participation with your own doctor first.
| CHU Amiens Picardie_Site Sud | Amiens, France | Recruiting |
| Institut Sainte Catherine | Avignon, France | Recruiting |
| Centre Hospitalier de la Côte Basque | Bayonne, France | Recruiting |
| CHU Jean Minoz | Besançon, France | Recruiting |
| Polyclinique Bordeaux Nord Aquitaine | Bordeaux, France | Recruiting |
| Centre François Baclesse | Caen, France | Recruiting |
| Centre Georges-François Leclerc | Dijon, France | Recruiting |
| CHD Vendee | La Roche-sur-Yon, France | Recruiting |
| Centre Oscar Lambret | Lille, France | Recruiting |
| Centre Léon Bérard | Lyon, France | Recruiting |
| Institut Paoli-Calmettes | Marseille, France | Recruiting |
| Institut Curie | Paris, France | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05973864